TY - JOUR
T1 - Comparative analysis of plasma metabolomics response to metabolic challenge tests in healthy subjects and influence of the FTO obesity risk allele
AU - Wahl, Simone
AU - Krug, Susanne
AU - Then, Cornelia
AU - Kirchhofer, Anna
AU - Kastenmüller, Gabi
AU - Brand, Tina
AU - Skurk, Thomas
AU - Claussnitzer, Melina
AU - Huth, Cornelia
AU - Heier, Margit
AU - Meisinger, Christa
AU - Peters, Annette
AU - Thorand, Barbara
AU - Gieger, Christian
AU - Prehn, Cornelia
AU - Römisch-Margl, Werner
AU - Adamski, Jerzy
AU - Suhre, Karsten
AU - Illig, Thomas
AU - Grallert, Harald
AU - Laumen, Helmut
AU - Seissler, Jochen
AU - Hauner, Hans
N1 - Funding Information:
Acknowledgments This work was funded by the Else Kroener-Fresenius Foundation, Bad Homburg v. d. H, Germany, the grant Virtual Institute ‘Molecular basis of glucose regulation and type 2 diabetes’ received from the Helmholtz Zentrum München, Neuherberg, Germany, the grant Clinical Cooperation Group ‘Nutrigenomics and type 2 diabetes’ received from the Helmholtz Zentrum München, Neuherberg, Germany, the Technische Universität München, Freising-Weihenstephan, and by funding from the German Federal Ministry for Education and Research (BMBF) to the German Center for Diabetes Research (DZD e. V.). WRM is funded by BMBF Grant no. 03IS2061B (project Gani_Med). KS is supported by ‘Biomedical Research Program’ funds at Weill Cornell Medical College in Qatar, a program funded by the Qatar Foundation. The KORA study group consists of A. Peters (speaker), R. Leidl, R. Holle, J. Heinrich, C. Meisinger, C. Strauch, and their coworkers, who are responsible for the design and conduct of the KORA studies. We gratefully acknowledge the contribution of all members of field staffs conducting the KORA study and thank all study probands participating in the study. The KORA research platform studies were initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Science, Research and Technology and by the State of Bavaria. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Julia Scarpa, Katharina Sckell and Arsin Sabunchi for metabolomics measurement performed at the Helmholtz Zentrum München, Genome Analysis Center, Meta-bolomics Core Facility, Neuherberg, Germany, and Jan Krumsiek for advice concerning weighted enrichment analysis.
PY - 2014/6
Y1 - 2014/6
N2 - The measurement of metabolites during intravenous or nutritional challenges may improve the identification of novel metabolic signatures which are not detectable in the fasting state. Here, we comprehensively characterized the plasma metabolomics response to five defined challenge tests and explored their use to identify interactions with the FTO rs9939609 obesity risk genotype. Fifty-six non-diabetic male participants of the KORA S4/F4 cohort, including 25 homozygous carriers of the FTO risk allele (AA genotype) and 31 carriers of the TT genotype were recruited. Challenges comprised an oral glucose tolerance test, a standardized high-fat high-carbohydrate meal and a lipid tolerance test, as well as an intravenous glucose tolerance test and a euglycemic hyperinsulinemic clamp. Blood was sampled for biochemical and metabolomics measurement before and during the challenges. Plasma samples were analyzed using a mass spectrometry-based metabolomics approach targeting 163 metabolites. Linear mixed-effects models and cluster analysis were performed. In both genotype groups, we observed significant challenge-induced changes for all major metabolite classes (amino acids, hexose, acylcarnitines, phosphatidylcholines, lysophosphatidylcholines and sphingomyelins, with corrected p-values ranging from 0.05 to 6.7E-37), which clustered in five distinct metabolic response profiles. Our data contribute to the understanding of plasma metabolomics response to diverse metabolic challenges, including previously unreported metabolite changes in response to intravenous challenges. The FTO genotype had only minor effects on the metabolite fluxes after standardized metabolic challenges.
AB - The measurement of metabolites during intravenous or nutritional challenges may improve the identification of novel metabolic signatures which are not detectable in the fasting state. Here, we comprehensively characterized the plasma metabolomics response to five defined challenge tests and explored their use to identify interactions with the FTO rs9939609 obesity risk genotype. Fifty-six non-diabetic male participants of the KORA S4/F4 cohort, including 25 homozygous carriers of the FTO risk allele (AA genotype) and 31 carriers of the TT genotype were recruited. Challenges comprised an oral glucose tolerance test, a standardized high-fat high-carbohydrate meal and a lipid tolerance test, as well as an intravenous glucose tolerance test and a euglycemic hyperinsulinemic clamp. Blood was sampled for biochemical and metabolomics measurement before and during the challenges. Plasma samples were analyzed using a mass spectrometry-based metabolomics approach targeting 163 metabolites. Linear mixed-effects models and cluster analysis were performed. In both genotype groups, we observed significant challenge-induced changes for all major metabolite classes (amino acids, hexose, acylcarnitines, phosphatidylcholines, lysophosphatidylcholines and sphingomyelins, with corrected p-values ranging from 0.05 to 6.7E-37), which clustered in five distinct metabolic response profiles. Our data contribute to the understanding of plasma metabolomics response to diverse metabolic challenges, including previously unreported metabolite changes in response to intravenous challenges. The FTO genotype had only minor effects on the metabolite fluxes after standardized metabolic challenges.
KW - Clamp
KW - FTO
KW - Gene-environment interaction
KW - Intravenous glucose tolerance test
KW - Metabolic challenge
KW - Metabolite profile
KW - Metabolomics
KW - Nutritional challenge
KW - Obesity
KW - Oral glucose tolerance test
KW - Oral lipid tolerance test
UR - http://www.scopus.com/inward/record.url?scp=84898416444&partnerID=8YFLogxK
U2 - 10.1007/s11306-013-0586-x
DO - 10.1007/s11306-013-0586-x
M3 - Article
AN - SCOPUS:84898416444
SN - 1573-3882
VL - 10
SP - 386
EP - 401
JO - Metabolomics
JF - Metabolomics
IS - 3
ER -